Literature DB >> 3263050

Ocular inflammatory effects of intravitreally-injected tumor necrosis factor.

J T Rosenbaum1, E L Howes, R M Rubin, J R Samples.   

Abstract

Many of the pathophysiologic effects of bacterial endotoxin have recently been attributed to a monokine, tumor necrosis factor (TNF). The rabbit eye is extremely sensitive to locally injected endotoxin. The authors have investigated the possible contribution of TNF to ocular inflammation in a rabbit model. The intravitreal injection of 10(5) to 5 X 10(5) units of recombinant human TNF produced a sustained disruption of the blood-aqueous barrier as manifested by elevated aqueous humor protein levels. In addition, 83% of rabbits receiving this dose of TNF developed hyperemia of limbal vessels and early neovascularization of the cornea. Many developed posterior synechiae (fibrous adhesions between the iris and the lens). TNF induced only a slight cellular response in the anterior chamber. Histologic studies confirmed the presence of new vessels and demonstrated a marked mononuclear infiltrate within and beneath the epithelium of the iris and ciliary body. Lower doses of TNF produced inconsistent results. Heating TNF completely destroyed its inflammatory effects. The time course of the ocular response to TNF and the quantity of recombinant protein needed to produce consistent effects were vastly different from effects observed with interleukin-1. For example, 24 hours after an intravitreal injection, 2.2 X 10(4) ng of TNF (5 X 10(5) units) produced significantly less protein extravasation and polymorphonuclear leukocyte infiltration than 4 ng of recombinant interleukin-1. Similarly, 24 hours after intravitreal injection, 1 ng of Escherichia coli endotoxin tended to be a more potent inflammatory stimulus than this quantity of TNF. These observations indicate that the ocular pathophysiologic effects of TNF can be readily distinguished from changes induced by either endotoxin or another endotoxin induced monokine, interleukin-1.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263050      PMCID: PMC1880652     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

Review 1.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

2.  Molecular cloning and expression in Escherichia coli of the cDNA coding for rabbit tumor necrosis factor.

Authors:  H Ito; S Yamamoto; S Kuroda; H Sakamoto; J Kajihara; T Kiyota; H Hayashi; M Kato; M Seko
Journal:  DNA       Date:  1986-04

3.  Monocyte chemotactic activity induced by intravitreal endotoxin.

Authors:  J T Rosenbaum; W Raymond
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-09       Impact factor: 4.799

4.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

5.  Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.

Authors:  P Libby; J M Ordovas; K R Auger; A H Robbins; L K Birinyi; C A Dinarello
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

6.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

7.  Molecular cloning of the complementary DNA for human tumor necrosis factor.

Authors:  A M Wang; A A Creasey; M B Ladner; L S Lin; J Strickler; J N Van Arsdell; R Yamamoto; D F Mark
Journal:  Science       Date:  1985-04-12       Impact factor: 47.728

8.  Ocular inflammatory effects of intravitreal interleukin 1.

Authors:  J T Rosenbaum; J R Samples; S H Hefeneider; E L Howes
Journal:  Arch Ophthalmol       Date:  1987-08

9.  Purification of rabbit tumor necrosis factor.

Authors:  S Abe; T Gatanaga; M Yamazaki; G Soma; D Mizuno
Journal:  FEBS Lett       Date:  1985-01-28       Impact factor: 4.124

10.  Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.

Authors:  P P Nawroth; I Bank; D Handley; J Cassimeris; L Chess; D Stern
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Anterior uveitis: clinical and research perspectives.

Authors:  J T Rosenbaum; T M Martin; S R Planck
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.

Authors:  Yanping Ding; Nan Song; Yongzhang Luo
Journal:  Cancer Microenviron       Date:  2012-04-20

3.  Mechanisms of edema formation in experimental autoimmune encephalomyelitis. The contribution of inflammatory cells.

Authors:  L Claudio; Y Kress; J Factor; C F Brosnan
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

4.  Why HLA-B27? My thirty-year quest: the Friedenwald lecture.

Authors:  James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

Review 5.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

Review 6.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

7.  Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules.

Authors:  E S Yi; T R Ulich
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

8.  Cellular response to intravitreal injection of endotoxin and xanthine oxidase in rabbits.

Authors:  M C McGahan; L N Fleisher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

9.  Adalimumab (humira™) in ophthalmology: a review of the literature.

Authors:  Piergiorgio Neri; Marta Lettieri; Cinzia Fortuna; Manuela Zucchi; Mara Manoni; Silvia Celani; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2010-10

Review 10.  Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia.

Authors:  Yael Sharon; Naomi Schlesinger
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.